Expressions of human epidermal growth factor receptor 2 and vascular endothelial growth factor in primary or recurrent metastatic breast cancers

Acta Academiae Medicinae Sinicae

Volumn 32, Issue 4, 2010, Pages 403-406

  Wang, Zhi Kuan ^a   Meng, Hai Yan ^b   Han, Chun ^a   Yang, Jun Lan ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b Infirmary of Administrative Office   (China)

Author keywords

Breast cancer; Human epidermal growth factor receptor 2; Primary focuses; Recurrent metastatic focuses; Vascular endothelial growth factor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; VASCULOTROPIN;

ARTICLE; BREAST CANCER; DISEASE ASSOCIATION; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; PRIMARY TUMOR; PROTEIN EXPRESSION; RECURRENT CANCER;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTOR, ERBB-2; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77957318164     PISSN: 1000503X     EISSN: None     Source Type: Journal    
DOI: 10.3881/j.issn.1000-503X.2010.04.009     Document Type: Article

References (10)

1. Colleoni M, Gelber S, Goldhirsch A, et al. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node positive breast cancer: International Breast Cancer Study Group Trial 13-93 [J]. J Clin Oncol, 2006, 24(9): 1323-1325.
2. Clere N, Bermont L, Fauconnet S, et al. The human papillomavirus type 18 E6 oncoprotein induces vascular endothelial growth factor 121 (VEGF121) transcription from the promoter through a p53-independent mechanism [J]. Exp Cell Res, 2007, 313(15): 3239-3250.
3. Berrak SG, Ozek MM, Canpolat C, et al. Association between DNA content and tumor suppressor gene expression and aggressiveness of atypical teratoid/rhabdoid tumors [J]. Childs Nerv Syst, 2002, 18(9-10): 485-491.
4. Zhu SC, Li R, Wang YX, et al. Impact of simultaneous assay, the PCNA, cyclinD1, and DNA content with specimens before and after preoperative radiotherapy on prognosis of esophageal cancer-possible incorporation into clinical TNM staging system [J]. World J Gastroenterol, 2005, 11(25): 3823-3829.
5. Erdem O, Dursun A, Coşkun U, et al. The prognostic value of p53 and c-erbB-2 expression, proliferative activity and angiogenesis in node-negative breast carcinoma [J]. Tumori, 2005, 91(1): 46-52.
6. Blackwell KL, Dewhirst MW, Liotcheva V, et al. HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors [J]. Clin Cancer Res, 2004, 10(12 Pt 1): 4083-4088.
7. Tai W, Qin B, Cheng K. Inhibition of breast cancer cell growth and invasiveness by dual silencing of HER-2 and VEGF [J]. Mol Pharm, 2010, 7(2): 543-556.